Imagine a world where a diagnosis of gastric cancer no longer carries the weight of a dire prognosis, where innovative treatments offer a real chance at long-term survival even for those in the early stages of this aggressive disease. This vision is inching closer to reality with the recent
A therapy that should unleash the immune system instead fuels a tumor’s growth, and the only way to see why is to listen to each cell speak for itself; that is the everyday paradox that single-cell RNA sequencing (scRNA-seq) now makes decipherable in real time. In oncology, this shift from average
Watching a single enzyme switch from a standstill to full sprint while decoding DNA inside a mammalian cell would have sounded like science fiction not long ago, yet that leap just became a measurable reality thanks to a single-molecule transcription platform that links factor binding to RNA
Ivan Kairatov has spent years at the intersection of structural biology and biopharma, translating difficult, dynamic molecules into practical insights that can power new therapeutics. In this conversation, he unpacks a “molecular film” of a self-splicing ribozyme—captured almost frame by frame—and
If bacteria aren’t the whole story of the tumor microenvironment, what crucial signals are being missed from fungi that quietly occupy the same space yet account for only a sliver of the sequencing reads but a disproportionate share of immune cues and clinical outcomes? That challenge has gained
In a world where patients often wait nearly a year for life-saving drugs to gain approval, a groundbreaking initiative by the FDA is slashing that timeline to mere weeks, promising a dramatic shift in biopharma. The Commissioner’s National Priority Voucher (CNPV) pilot program is not just speeding
